DDInter1387 DDInter1376
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Panobinostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen